Cybin Inc. (CYBN), a clinical-stage neuropsychiatry company, is making strides in developing psychedelic-based therapeutics for mental health conditions. The company recently summarized its 2024 achievements and outlined key milestones for 2025, focusing on its pipeline of tryptamine serotonin receptor agonists.
CYB003 for Major Depressive Disorder
CYB003, a deuterated psilocin analog, is Cybin's leading program for the adjunctive treatment of major depressive disorder (MDD). In March 2024, CYB003 received FDA Breakthrough Therapy Designation, a significant milestone that expedites its development and acknowledges the unmet need in MDD treatment. This designation provides an expedited review pathway and includes all "fast track" program features.
Phase 2 study results of CYB003 in MDD demonstrated a 100% response rate and a 71% remission rate among participants who received two 16 mg doses. The mean change from baseline in MADRS (Montgomery-Asberg Depression Rating Scale) was approximately 23 points after two doses of 16 mg. These findings led to the initiation of the multinational Phase 3 PARADIGM program, evaluating CYB003 in MDD patients.
The PARADIGM program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND). The APPROACH study has been initiated and will enroll 220 participants at 36 clinical sites across the U.S. and Europe, with topline results expected in 2026. The EMBRACE study will enroll 330 participants at sites across the U.S. and Europe and is expected to commence by mid-2025. The EXTEND study is expected to begin 12 weeks after commencement of APPROACH and EMBRACE, respectively.
CYB004 for Generalized Anxiety Disorder
CYB004, a deuterated dimethyltryptamine (DMT) in intramuscular form, is being developed for the treatment of generalized anxiety disorder (GAD). Cybin commenced a Phase 2 proof-of-concept study for CYB004 in GAD, with topline efficacy data expected in early 2025. The Phase 2 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. The study is being conducted at sites in the U.S.
CYB005 and Future Research
Cybin also announced the grant of the first U.S. Composition of Matter patent in support of its CYB005 phenethylamines program. Cybin is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System disorders and continues to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline.
Leadership Perspective
"In 2024, we made significant progress toward our goal of transforming the mental health treatment landscape," said Doug Drysdale, Chief Executive Officer of Cybin. "Our clinical pipeline of tryptamine serotonin receptor agonists – notably CYB003, our proprietary deuterated psilocin program in development for the adjunctive treatment of MDD, and CYB004, our deuterated dimethyltryptamine, in intramuscular form being developed for the treatment of GAD - achieved several critical benchmarks."
Cybin's advancements in psychedelic therapeutics represent a promising approach to addressing the unmet needs in mental health treatment. With ongoing clinical trials and a focus on innovative drug development, Cybin is positioned to potentially revolutionize the treatment of MDD and GAD.
